We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| IS Pharma | ISPH | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 87.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 87.00 | 87.00 |
| Top Posts |
|---|
Posted at 25/2/2011 16:35 by red ninja Sinclair Pharma cuts first-half loss24/02/2011 Robert Tyerman Merger candidate Sinclair Pharma (SPH) has slashed interim losses 73 per cent to £3.6 million, helped by new product launches and acquisitions. The fully-listed company, steered by entrepreneurial chief executive officer Chris Spooner, increased turnover 28 per cent to £14.1 million in the six months to December and cut net debt from £15.2 million to £2.4 million. Sinclair, which specialises in oral health, dermatology and wound care and is still discussing a possible merger with AIM counter IS Pharma, expanded in the first half by buying wound care products Flammazine and Flammacerium from Belgium's Solvay Group, helped by a £19 million funding at 28p in October. The company bought European licensing rights to US group Advanced Bio Technologies' Kelo-Cote scar reduction formulation and launched its Atopiclair eczema and dermatitis cream in France and Spooner says first Asian product launches are expected in the middle of this year. Highlighted by Growth Company Investor at 28p last autumn, Sinclair shares now trade at 37p, valuing the company at £86 million. Hold on. |
Posted at 06/12/2010 16:57 by gogoneko Having seen some disastrous investment decisions elsewhere by Blackrock I can't say their choices are faultless, but hopefully here they won't have any cause to regret their ISPH investment. Nevertheless it's nice to have an expanding institutional investor base from purchases at reasonably fair prices. |
Posted at 14/11/2010 13:28 by red ninja IS Pharma goes on acquisition trail A pharmaceutical group which specialises in buying, developing and marketing hospital medicines is to go on the acquisition trail after raising £12.5m in a share placing. Chester-based IS Pharma, which is listed on AIM and has a market value of £29.9m, has placed 15.6 million new ordinary shares at 80p each. It follows the £3.6m it raised last month after placing 4.6 million shares with the London-based healthcare investor Abingworth at 77p each. The company also unveiled interim results for the six months to September 30, with pre-tax profits trebling to £1.4m on the back of a 10% increase in sales to £6.5m, and said it would use the cash to cover milestone payments and fund future acquisitions. Chief executive Tim Wright said: "At the time of the recent strategic investment by Abingworth, we were asked by a number of our existing shareholders to give them an opportunity to further invest in IS Pharma. This Placing is in response to these requests and was oversubscribed. "We are delighted that so many of our existing shareholders have supported this fundraising and we are pleased to welcome a number of significant new institutions who have chosen to support IS Pharma at this important stage in the growth of the company." -------------------- |
Posted at 14/6/2010 16:57 by red ninja Nice write-up in Shares Mag 10/6/10 (copied from iii)"Small cap investors should look to snap up IS Pharma (ISPH:AIM) as the company gains momentum with recent pharmaceutical lines and rolls out new products. The specialty drug company is profitable and showing good growth. It is also relatively low risk, due to its strategy of buying late-stage development products, thus avoiding most of the dangers inherent in drug research." "buy at 68p" |
Posted at 04/6/2010 00:08 by gogoneko There's also the issue of transparency.Why didn't the ISPH directors inform all investors of the failed Lucassin NDA submission when it was known to Orphan back in November? In December they wrote : "In the US, the FDA has issued a Complete Response Letter for Lucassin (US tradename for Variquel). Our US partners plan to meet with the FDA in the coming months.". Why not provide an explanation, or at least why not inform all investors so that everyone could have offloaded in anticipation of a 30-40% slump in the shares price! Also there was no update announced on the recent agreement between Orphan and Ikaria regaring Ikaria's takeover of the NDA process - have further problems arisen? Considering the royalty revenues from Lucassin form part of ISPH's projected revenues, investors should be updated on progress, or lack of it, as soon as it becomes available. |
Posted at 25/3/2010 10:55 by gogoneko clogue,You somehow appear to expect listed company boards to notify investors of improper actions! In the real world that doesn't happen, does it? I'm sure that the vast majority of investors reading these posts can provide many examples of seriously unpleasant activity by corporate directors which have not been in the interest of shareholders... but do they represent "improper actions"? Of course not, they represent bad actions, which is what IMO we have here. I prefer to interpret (incorrectly or otherwise!) what I read, not simply read and accept, so maybe this is why there's a difference between our viewpoints. |
Posted at 22/3/2010 10:04 by clogue At the time of the last results we were told that Volplex and Isoplex were being run down and they were concentrating on "our most profitable and sustainable products".The company has recently bought the european right to market Episil and it looks like this is just a bit of prudent book balancing. Management are doing exactly what I expect of them and I see no reason to doubt their ability to manage, do deals and grow the company. If I lose faith in this management I will simply sell and move on, as this is the only logical step I can take as a private investor, but I have seen nothing that is giving me second thoughts. |
Posted at 22/2/2010 13:39 by carwhite the fact that we are now approaching the 60p I forecasted is clearly enough basis for me!I wonder how many little punters bought on the irresponsible advice of Growth Company Investor? If we see 60p we will see around 50p. |
Posted at 21/2/2010 21:57 by red ninja Well Car White that was a true factual statement and it remain true.They are still s STRONG BUY for Growth Company Investor. This contrasts with your regular deramps with no basis given for your views. |
Posted at 21/2/2010 21:31 by carwhite Red Ninja you posted this on the 15 Jan then they fell............They are still a STRONG BUY for Growth Company Investor.I WISH YOU UNREMITTING RAMPAGERS WOULD GIVE IT A BREAK AS YOU REALLY KNOW NOTHING! |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
